

Jeanne Tie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2033169/publications.pdf>

Version: 2024-02-01

115
papers

10,932
citations

159585

30
h-index

36028

97
g-index

116
all docs

116
docs citations

116
times ranked

15201
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Biomarkers in Locally Advanced Rectal Cancer: A Review. <i>Clinical Colorectal Cancer</i> , 2022, 21, 36-44. | 2.3 | 4 |
| 2 | Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, . | 2.9 | 1 |
| 3 | Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 47-47. | 1.6 | 0 |
| 4 | A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. <i>BMC Cancer</i> , 2022, 22, 222. | 2.6 | 3 |
| 5 | A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. <i>British Journal of Cancer</i> , 2022, 127, 126-136. | 6.4 | 9 |
| 6 | Landscape of <i>KRAS</i> G12C ⁺ , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i> -Mutated Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100245. | 3.0 | 31 |
| 7 | The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 6619-6631. | 1.5 | 5 |
| 8 | Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 279-298. | 3.8 | 11 |
| 9 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre. <i>ANZ Journal of Surgery</i> , 2022, , . | 0.7 | 2 |
| 10 | Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2261-2272. | 27.0 | 337 |
| 11 | The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2022, , . | 1.0 | 4 |
| 12 | Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021, 20, e21-e34. | 2.3 | 4 |
| 13 | Effect of Aspirin on Cancer Incidence and Mortality in Older Adults. <i>Journal of the National Cancer Institute</i> , 2021, 113, 258-265. | 6.3 | 80 |
| 14 | Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026. | 5.1 | 77 |
| 15 | Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100637. | 2.0 | 11 |
| 16 | Impact of adjuvant chemotherapy and patient age on patterns of metastatic recurrence in stage III colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 122-122. | 1.6 | 1 |
| 17 | Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. <i>Diagnostics</i> , 2021, 11, 103. | 2.6 | 33 |
| 18 | ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. <i>Cancers</i> , 2021, 13, 346. | 3.7 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. Targeted Oncology, 2021, 16, 227-236. | 3.6 | 2 |
| 20 | Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Metaanalysis of Oncological and Operative Outcomes. Annals of Surgical Oncology, 2021, 28, 7476-7486. | 1.5 | 49 |
| 21 | Clinical relevance of circulating tumour DNA in colorectal cancer. ANZ Journal of Surgery, 2021, 91, 774-775. | 0.7 | 1 |
| 22 | Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Medicine, 2021, 18, e1003620. | 8.4 | 88 |
| 23 | FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy.. Journal of Clinical Oncology, 2021, 39, e15571-e15571. | 1.6 | 0 |
| 24 | Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nature Biotechnology, 2021, 39, 1220-1227. | 17.5 | 40 |
| 25 | Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases. Clinical Colorectal Cancer, 2021, , . | 2.3 | 1 |
| 26 | Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. Pharmacoeconomics, 2021, 39, 953-964. | 3.3 | 14 |
| 27 | Reply to: Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not. Annals of Surgical Oncology, 2021, 28, 795-796. | 1.5 | 0 |
| 28 | Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. Acta Oncologica, 2021, 60, 482-490. | 1.8 | 1 |
| 29 | Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?. Current Oncology Reports, 2021, 23, 140. | 4.0 | 3 |
| 30 | Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313. | 4.4 | 15 |
| 31 | Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience. Journal of Gastrointestinal Surgery, 2020, 24, 899-906. | 1.7 | 27 |
| 32 | Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. Internal Medicine Journal, 2020, 50, 165-172. | 0.8 | 1 |
| 33 | Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. , 2020, 8, e001006. | | 62 |
| 34 | Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics, 2020, 38, 1263-1275. | 3.3 | 3 |
| 35 | CD8 ⁺ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survival. Clinical and Translational Immunology, 2020, 9, e1155. | 3.8 | 8 |
| 36 | Tailoring immunotherapy with liquid biopsy. Nature Cancer, 2020, 1, 857-859. | 13.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. <i>Visceral Medicine</i> , 2020, 36, 388-396. | 1.3 | 4 |
| 38 | Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 3662-3670. | 7.0 | 107 |
| 39 | Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863. | 7.1 | 50 |
| 40 | Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 147-159. | 3.8 | 9 |
| 41 | Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 932. | 7.1 | 1 |
| 42 | Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. <i>Growth Factors</i> , 2020, 38, 127-136. | 1.7 | 0 |
| 43 | Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 527-539. | 1.9 | 12 |
| 44 | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2019, 9, 37. | 2.5 | 6 |
| 45 | Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710. | 7.1 | 383 |
| 46 | The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019, 145, 540-547. | 5.1 | 15 |
| 47 | Emerging strategies in the initial management of locally advanced rectal cancer. <i>Future Oncology</i> , 2019, 15, 2955-2965. | 2.4 | 6 |
| 48 | Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. <i>ANZ Journal of Surgery</i> , 2019, 89, 1035-1040. | 0.7 | 14 |
| 49 | Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118. | 7.1 | 152 |
| 50 | Registry-based randomized clinical trials as a method to improve cancer care in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 188-189. | 1.1 | 4 |
| 51 | Circulating tumour DNA in early stage colorectal cancer: can blood tell all?. <i>Annals of Translational Medicine</i> , 2019, 7, S358-S358. | 1.7 | 0 |
| 52 | Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer. <i>Growth Factors</i> , 2019, 37, 209-225. | 1.7 | 6 |
| 53 | Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1195-1203. | 1.3 | 18 |
| 54 | Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019, 49, 446-454. | 0.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671. | 12.1 | 234 |
| 56 | Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic. <i>Oncology & Hematology Review</i> , 2019, 15, 33. | 0.2 | 1 |
| 57 | Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930. | 12.6 | 1,872 |
| 58 | Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. <i>Seminars in Cancer Biology</i> , 2018, 52, 241-252. | 9.6 | 12 |
| 59 | How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e167-e174. | 1.1 | 0 |
| 60 | Clinical guidance for radioiodine refractory differentiated thyroid cancer. <i>Clinical Endocrinology</i> , 2018, 88, 529-537. | 2.4 | 27 |
| 61 | Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1-3. | 3.1 | 13 |
| 62 | Precision oncology using a clinician-directed, tailored approach to molecular profiling. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 84-90. | 1.1 | 2 |
| 63 | The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , 2018, 57, 1438-1444. | 1.8 | 78 |
| 64 | Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond. <i>Future Oncology</i> , 2018, 14, 2725-2739. | 2.4 | 14 |
| 65 | Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, e569-e577. | 2.3 | 23 |
| 66 | Reinventing the randomized controlled trial in medical oncology: The registry-based trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 365-373. | 1.1 | 30 |
| 67 | Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3516-3516. | 1.6 | 19 |
| 68 | A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 463-474. | 3.6 | 64 |
| 69 | Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207. | 7.1 | 438 |
| 70 | The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 314-321. | 1.1 | 7 |
| 71 | Examining the impact of regular aspirin use and <i>PIK3CA</i> mutations on survival in stage 2 colon cancer. <i>Internal Medicine Journal</i> , 2017, 47, 88-98. | 0.8 | 16 |
| 72 | The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3521-3521. | 1.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 4101-4101. | 1.6 | 9 |
| 74 | Treatment sequencing and outcomes in synchronous metastatic rectal cancer.. Journal of Clinical Oncology, 2017, 35, 750-750. | 1.6 | 1 |
| 75 | Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. International Journal of Cancer, 2016, 138, 671-678. | 5.1 | 56 |
| 76 | Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer. Clinical Cancer Research, 2016, 22, 3488-3498. | 7.0 | 26 |
| 77 | Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92. | 12.4 | 1,036 |
| 78 | Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine. Clinical Chemistry, 2016, 62, 796-798. | 3.2 | 12 |
| 79 | RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 95-103. | 2.3 | 30 |
| 80 | Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, e9-e15. | 2.3 | 45 |
| 81 | Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. Clinical Colorectal Cancer, 2016, 15, e125-e132. | 2.3 | 8 |
| 82 | Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.. Journal of Clinical Oncology, 2016, 34, 650-650. | 1.6 | 2 |
| 83 | Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 685-685. | 1.6 | 0 |
| 84 | Immune profile and survival outcomes in stage 2 colon cancer.. Journal of Clinical Oncology, 2016, 34, 3576-3576. | 1.6 | 1 |
| 85 | Radioembolization for hepatocellular carcinoma: current role and future directions â€” the medical oncologist's perspective. Hepatic Oncology, 2015, 2, 117-132. | 4.2 | 0 |
| 86 | Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 262-271. | 1.1 | 6 |
| 87 | Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer. PLoS ONE, 2015, 10, e0120425. | 2.5 | 59 |
| 88 | Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. Journal of Cancer Epidemiology, 2015, 2015, 1-8. | 1.1 | 13 |
| 89 | Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. Clinical Colorectal Cancer, 2015, 14, 185-191. | 2.3 | 42 |
| 90 | Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncologica, 2015, 54, 487-492. | 1.8 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1033-1048. | 3.1 | 0 |
| 92 | Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Targeted Oncology, 2015, 10, 179-188. | 3.6 | 35 |
| 93 | A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Targeted Oncology, 2015, 10, 99-109. | 3.6 | 45 |
| 94 | Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia.. Journal of Clinical Oncology, 2015, 33, e14648-e14648. | 1.6 | 0 |
| 95 | Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24. | 12.4 | 3,665 |
| 96 | Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 361-367. | 1.1 | 6 |
| 97 | Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, e14558-e14558. | 1.6 | 1 |
| 98 | Resection of colorectal cancer (CRC) metastases in routine practice.. Journal of Clinical Oncology, 2014, 32, 599-599. | 1.6 | 0 |
| 99 | Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 386-386. | 1.6 | 1 |
| 100 | Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice.. Journal of Clinical Oncology, 2014, 32, e14540-e14540. | 1.6 | 1 |
| 101 | Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care.. Journal of Clinical Oncology, 2014, 32, e17637-e17637. | 1.6 | 0 |
| 102 | Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer.. Journal of Clinical Oncology, 2014, 32, e14518-e14518. | 1.6 | 0 |
| 103 | Second primary colorectal cancer in the era of prevalent screening and imaging. ANZ Journal of Surgery, 2013, 83, 963-967. | 0.7 | 6 |
| 104 | Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. Journal of Clinical Oncology, 2013, 31, 410-410. | 1.6 | 1 |
| 105 | Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation.. Journal of Clinical Oncology, 2013, 31, 426-426. | 1.6 | 28 |
| 106 | Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?. Journal of Clinical Oncology, 2013, 31, 534-534. | 1.6 | 0 |
| 107 | Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, e14608-e14608. | 1.6 | 0 |
| 108 | Microsatellite Instability Status Is Critical to Analysis of Survival in Stage II Colon Cancer. Journal of Clinical Oncology, 2012, 30, 675-676. | 1.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Prescribing patterns for bevacizumab in first-line metastatic colorectal cancer: Exploring the introduction of a new drug into routine clinical practice.. Journal of Clinical Oncology, 2012, 30, 665-665. | 1.6 | 1 |
| 110 | Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A two-year review of routine practice.. Journal of Clinical Oncology, 2012, 30, 682-682. | 1.6 | 1 |
| 111 | Antiangiogenic Therapies Targeting the Vascular Endothelia Growth Factor Signaling System. Critical Reviews in Oncogenesis, 2012, 17, 51-67. | 0.4 | 46 |
| 112 | <i>KRAS</i> Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. Clinical Cancer Research, 2011, 17, 1122-1130. | 7.0 | 193 |
| 113 | Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer, 2011, 117, 4623-4632. | 4.1 | 624 |
| 114 | Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF ^{V600E} mutation. International Journal of Cancer, 2011, 128, 2075-2084. | 5.1 | 200 |
| 115 | Differentiation of tumor recurrence from radiation necrosis in high-grade gliomas using 201Tl-SPECT. Journal of Clinical Neuroscience, 2008, 15, 1327-1334. | 1.5 | 42 |